Skip to main content
SpringerLink
Log in

Tocilizumab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1255 Accesses

Abstract

Tocilizumab (Actemra®, RoActemra®, Genentech/Roche) is a humanized IgG1k monoclonal antibody against interleukin-6 receptor (IL-6R), thus inhibiting the biological activity of IL-6, and thereby reducing the production of acute phase molecules active in inflammatory and autoimmune processes. Tocilizumab was approved in Japan in April 2005 for the treatment of multicentric Castleman’s disease, and in April 2008 for the treatment of adult rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (SJIA), and polyarticular juvenile idiopathic arthritis (PJIA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tocilizumab (RoActemra®) WC500054888 Assessment Report EMEA, Feb 2009

    Google Scholar 

  2. Tocilizumab (Actemra®) Briefing Document for FDA-AAC, Roche July 2008

    Google Scholar 

  3. Tocilizumab (Actemra®) BLA125276 Medical Review FDA, Nov 2009

    Google Scholar 

  4. Tocilizumab (Actemra®) BLA125276/22 Clinical Review FDA, Oct 2010

    Google Scholar 

  5. Tocilizumab (RoActemra®) WC500094604 Scientific Discussion EMEA, July 2010

    Google Scholar 

  6. Tocilizumab (RoActemra®) WC500111086 Assessment Report EMEA, Aug 2011

    Google Scholar 

  7. Tocilizumab (RoActemra®) WC500054890 EPAR Annex I EMEA, Jan 2012 Tocilizumab (Actemra®)

    Google Scholar 

  8. Tocilizumab (Actemra®) Prescribing Information Roche, Oct 2012

    Google Scholar 

  9. Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106:2627–2632

    Google Scholar 

  10. Woo P, Wilkinson N, Prieur A-M et al (2005) Open-label phase II trial on single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7:R1281–1288

    Google Scholar 

  11. Yokota S, Tanaka T, Kishimoto T (2012) Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskel Dis doi:10.1177/1759720X12455960

  12. De Benedetti F, Brunner H, Ruperto N et al (2010) Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum 62 (S 10):1434

    Google Scholar 

  13. Tanaka T, Narazaki M, Kishimoto T (2012) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 585:3699–3709

    Google Scholar 

  14. Navarro-Millàn, Singh JA, Curtis JR (2012) Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 34:788–802

    Google Scholar 

  15. Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer. Cancer 110:1911–1928

    Google Scholar 

  16. Stubenrauch K, Wessels U, Birnboeck H et al (2010) Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 32:1597–1609

    Google Scholar 

  17. Kessler EA, Vora SS, Verbsky JW (2012) Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Ped Rheum 10:30–34

    Google Scholar 

  18. Yoshida A, Ota T, Sasaoka S et al (2012) Necrotizing fasciitis in a patient with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol (2012) 22:317–318

    Google Scholar 

  19. Van de Sande MGH, van Slobbe-Bjilsma ER (2012) Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab. Rheumatology 51:578–580

    Google Scholar 

  20. Kobayashi K, Okamoto Y, Inoue H et al (2009) Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 48:1307–1309

    Google Scholar 

  21. Campbell L, Chen C, Bhagat SS et al (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50:552–562

    Google Scholar 

  22. Koike T, Harigai M, Inokuma S et al (2011) Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis doi:10.1136/ard.2011.151092

  23. Bykerk VP, Andrew JK, Alvaro-Gracia J et al (2012) Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis 71:1950–1954

    Google Scholar 

  24. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy. JAMA 308:898–908

    Google Scholar 

  25. Dougados M, Kissel K, Sheeran T et al (2013) Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACR-RAY). Ann Rheum Dis 72:43–50

    Google Scholar 

  26. El-Osta HE, Kurzrock R (2011) Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 16:497–511

    Google Scholar 

  27. Polizzotto MN, Uldrick TS, Hu D et al (2012) Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol 3: 1-9 doi:10.3389/fmicb.2012.00073

  28. Nishimoto N, Sasai M, Shirma Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:36–61

    Google Scholar 

  29. Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman’s disease. Blood 106:2627–2632

    Google Scholar 

  30. Lepka FK, Wendling D, Soubrier M et al (2012) Il IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther 14:R53-61

    Google Scholar 

  31. Mancheño BB, Perin F, Rodriguez-Vasquez del Rey MdM et al (2012) Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 130;e1720 doi:10.1542/peds.2012-1384

  32. Raine C, Hamdulay SS, Khanna M et al (2012) An unusual complication of tocilizumab therapy: MRI appearances of thenar eminence pyomyositis. Jt Bone Spine doi:10.1016/j.jbspin.2012.10.015

  33. Sakai R, Tanaka M, Nanki T et al (2012) Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different molecules. Ann Rheum Dis 71:1820–1826

    Google Scholar 

  34. Shoels M, Aletaha D, Smolen JS et al (2012) Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 71:1303–1308

    Google Scholar 

  35. Simsek I, Yazici Y (2012) Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review. Arthritis Care Res 64:1611–1616

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 63 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Tocilizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_36

Download citation

Publish with us

Policies and ethics

Search

Navigation